Logo image of PASG

PASSAGE BIO INC (PASG) Stock Overview

USA - NASDAQ:PASG - US7027122099 - Common Stock

6.95 USD
-0.05 (-0.71%)
Last: 9/15/2025, 8:00:02 PM

PASG Key Statistics, Chart & Performance

Key Statistics
52 Week High26.6
52 Week Low5.12
Market Cap22.10M
Shares3.18M
Float3.04M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-18.16
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11
IPO02-28 2020-02-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


PASG short term performance overview.The bars show the price performance of PASG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

PASG long term performance overview.The bars show the price performance of PASG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of PASG is 6.95 USD. In the past year, price decreased by -48.97%.

PASSAGE BIO INC / PASG Daily stock chart

PASG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.55 384.42B
AMGN AMGEN INC 12.58 147.73B
GILD GILEAD SCIENCES INC 14.54 139.64B
VRTX VERTEX PHARMACEUTICALS INC 23.21 100.82B
REGN REGENERON PHARMACEUTICALS 12.55 60.69B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.45B
ARGX ARGENX SE - ADR 81.64 46.32B
ONC BEONE MEDICINES LTD-ADR 5.81 39.50B
INSM INSMED INC N/A 30.26B
NTRA NATERA INC N/A 23.63B
BNTX BIONTECH SE-ADR N/A 23.53B
BIIB BIOGEN INC 8.95 21.01B

About PASG

Company Profile

PASG logo image Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Company Info

PASSAGE BIO INC

One Commerce Square, 2005 Market Street, 39Th Floor

PHILADELPHIA PENNSYLVANIA 19103 US

CEO: Bruce Goldsmith

Employees: 60

PASG Company Website

PASG Investor Relations

Phone: 12678660312

PASSAGE BIO INC / PASG FAQ

What is the stock price of PASSAGE BIO INC today?

The current stock price of PASG is 6.95 USD. The price decreased by -0.71% in the last trading session.


What is the ticker symbol for PASSAGE BIO INC stock?

The exchange symbol of PASSAGE BIO INC is PASG and it is listed on the Nasdaq exchange.


On which exchange is PASG stock listed?

PASG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PASSAGE BIO INC stock?

11 analysts have analysed PASG and the average price target is 65.54 USD. This implies a price increase of 842.95% is expected in the next year compared to the current price of 6.95. Check the PASSAGE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PASSAGE BIO INC worth?

PASSAGE BIO INC (PASG) has a market capitalization of 22.10M USD. This makes PASG a Nano Cap stock.


How many employees does PASSAGE BIO INC have?

PASSAGE BIO INC (PASG) currently has 60 employees.


What are the support and resistance levels for PASSAGE BIO INC (PASG) stock?

PASSAGE BIO INC (PASG) has a support level at 6.94 and a resistance level at 7.04. Check the full technical report for a detailed analysis of PASG support and resistance levels.


Should I buy PASSAGE BIO INC (PASG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PASSAGE BIO INC (PASG) stock pay dividends?

PASG does not pay a dividend.


When does PASSAGE BIO INC (PASG) report earnings?

PASSAGE BIO INC (PASG) will report earnings on 2025-11-11.


What is the Price/Earnings (PE) ratio of PASSAGE BIO INC (PASG)?

PASSAGE BIO INC (PASG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.16).


What is the Short Interest ratio of PASSAGE BIO INC (PASG) stock?

The outstanding short interest for PASSAGE BIO INC (PASG) is 3.2% of its float. Check the ownership tab for more information on the PASG short interest.


PASG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PASG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PASG. The financial health of PASG is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PASG Financial Highlights

Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -18.16. The EPS decreased by -188.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -71.79%
ROE -148.61%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%43.08%
Sales Q2Q%N/A
EPS 1Y (TTM)-188.71%
Revenue 1Y (TTM)N/A

PASG Forecast & Estimates

11 analysts have analysed PASG and the average price target is 65.54 USD. This implies a price increase of 842.95% is expected in the next year compared to the current price of 6.95.


Analysts
Analysts85.45
Price Target65.54 (843.02%)
EPS Next Y11.02%
Revenue Next YearN/A

PASG Ownership

Ownership
Inst Owners51.79%
Ins Owners0.21%
Short Float %3.2%
Short Ratio0.4